No CrossRef data available.
Protein a Immunoadsorption Column Versus Splenectomy in the Treatment of Steroid-resistant Immune Thrombocytopenic Purpura: A Cost-Effectiveness Analysis
Published online by Cambridge University Press: 10 March 2009
Abstract
The protein A immunoadsorption column is a new treatment for immune thrombocytopenic purpura (ITP). We used a decision-analytic approach with a Markov process to model the cost effectiveness of this treatment compared with splenectomy for steroid-resistant ITP patients. Data informing the model were obtained from published literature, a panel of physicians, and public databases. We found initial treatment with the protein A immunoadsorption column to be less expensive and more effective than initial treatment with splenectomy.
- Type
- General Essays
- Information
- International Journal of Technology Assessment in Health Care , Volume 12 , Issue 3 , Summer 1996 , pp. 436 - 449
- Copyright
- Copyright © Cambridge University Press 1996
References
REFERENCES
1.Akwari, O. E., Itani, K. M. F., Coleman, R. E., & Rosse, W. F.Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP). Annals of Surgery, 1987, 206, 529–41.Google Scholar
2.Balint, J. P., Snyder, H. W., Cochran, S. K., & Jones, F. R.Long-term response of immune thrombocytopenia to extracorporeal immunoadsorption. Lancet, 1991, 337, 1106.Google Scholar
3.Beck, J. R., & Pauker, S. G.The Markov process in medical prognosis. Medical Decision Making, 1983, 3, 419–58.Google Scholar
4.Berchtold, P., & McMillan, R.Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood, 1989, 74, 2309–17.CrossRefGoogle ScholarPubMed
5.Chirletti, P., Cardi, M., Barillari, P., et al. Surgical treatment of immune thrombocytopenic purpura. World Journal of Surgery, 1992, 16, 1001–05.CrossRefGoogle ScholarPubMed
6.Churchill, D. N., Torrance, G. W., Taylor, D. W., et al. Measurement of quality of life in end-stage renal disease: The time trade-off approach. Clinical and Investigative Medicine, 1987, 10, 14–20.Google ScholarPubMed
7.Dalkey, N. C. The Delphi method: An experimental study of group opinion. Rand Corporation, 06 1969.Google Scholar
8.Dameshek, W., Rubio, F. Jr., Mahoney, J. P., Reeves, W. H., & Burgin, L. A.Treatment of idiopathic thrombocytopenic purpura with prednisone. The Journal of the American Medical Association, 1958, 166, 1805–15.Google Scholar
9.Derrington, M. C., & Smith, G.A review of studies of anaesthetic risk, morbidity, and mortality. British Journal of Anaesthesiology, 1987, 59, 815–33.CrossRefGoogle ScholarPubMed
10.Doan, C. A., Bouroncle, B. A., & Wiseman, B. K.Idiopathic and secondary thrombocyto penic purpura. Annals of Internal Medicine, 1960, 53, 861–76.Google Scholar
11.Fryback, D. G., Dasbach, E. J., Klein, R., et al. The Beaver Dam health outcomes study: Initial catalog of health-state quality factors. Medical Decision Making, 1993,13, 89–102.Google Scholar
12.Gage, B. E., Scott, J., & Owens, D. K.Marginal cost-utility of warfarin and aspirin in elderly patients with non-valvular atrial fibrillation (abstract). Medical Decision Making, 1993, 13, 3.Google Scholar
13.George, J. N., El-Harake, M. A., & Raskob, G. E.Chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 1994, 331, 1207–11.CrossRefGoogle ScholarPubMed
14.Guthrle, T. H., & Oral, A.Immune thrombocytopenla purpura: A pilot study of staphylococcal protein A immunomodulation in refractory patients. Seminars in Hematology, 1989, 26 (suppl. 1), 3–9.Google Scholar
15.Hylek, E. M., & Singer, D. E.Risk factors for intracranial hemorrhage in outpatients taking warfarin. Annals of Internal Medicine, 1994, 120, 897–902.CrossRefGoogle ScholarPubMed
16.Kamlet, M. S.A framework for cost-utility analysis of government health care programs Washington, DC: U.S. Department of Health and Human Services, 1992.Google Scholar
17.Karpatkin, S.Autoimmune thrombocytopenic purpura. Seminars in Hematology, 1985, 22, 260–88.Google Scholar
18.Kuppermann, M., Shiboski, S., Feeny, D., et al. Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Unpublished manuscript.Google Scholar
19.Muroi, K., Sasaki, R., & Miura, Y.The effect of immunoadsorption therapy by a protein A column on patients with thrombocytopenia. Seminars in Hematology, 1989, 26(suppl. 1), 10–14.Google Scholar
20.National Center for Health Statistics. Life tables: Vital statistics of the United States, 1988. 1991, 2.Google Scholar
21.O’Meara, J. J., McNutt, R. A., Evans, A. T., et al. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. New England Journal of Medicine, 1994, 330, 1864–69.Google Scholar
22.Scully, R. E., Mark, E. J., McNeely, W. F., & McNeely, B. U.Case records of the Massachusetts General Hospital. New England Journal of Medicine, 1994, 331, 792–800.Google Scholar
23.Singer, D. B.Postsplenectomy sepsis. Perspectives of Pediatric Pathology, 1973, 1, 285–311.Google Scholar
24.Snyder, H. W., Cochran, S. K., Balint, J. P., et al. Experience with protein A immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood, 1992, 79, 2237–45.Google Scholar
25.Snyder, H.W., Cochran, S.K., Balint, J. P., & Jones, F.R.Immune modulation leading to resolution of acute and treatment-resistant immune thrombocytopenic purpura in patients treated with protein A immunoadsorption. Therapeutic Plasmapheresis, 1993,12, 611–14.Google Scholar
26.Sonnenberg, F. A., & Beck, J. R.Markov models in medical decision making: A practical guide. Medical Decision Making, 1993, 13, 322–38.CrossRefGoogle ScholarPubMed
27.Torrance, G. W., & Feeny, D.Utilities and quality-adjusted life years. International Journal of Technology Assessment in Health Care, 1989, 5, 559–75.Google Scholar
28.Weinstein, M. C., & Fineberg, H. V. (eds.). Clinical decision analysis. Philadelphia, PA: W. B. Saunders Co., 1980.Google Scholar